JOP20250144A1 - عوامل مساعدة لمستقبل أميلين - Google Patents
عوامل مساعدة لمستقبل أميلينInfo
- Publication number
- JOP20250144A1 JOP20250144A1 JOJO/P/2025/0144A JOP20250144A JOP20250144A1 JO P20250144 A1 JOP20250144 A1 JO P20250144A1 JO P20250144 A JOP20250144 A JO P20250144A JO P20250144 A1 JOP20250144 A1 JO P20250144A1
- Authority
- JO
- Jordan
- Prior art keywords
- amylin
- help
- factors
- development
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22215958 | 2022-12-22 | ||
| US18/512,512 US12116388B2 (en) | 2022-12-22 | 2023-11-17 | Amylin receptor agonists |
| PCT/EP2023/087353 WO2024133739A1 (en) | 2022-12-22 | 2023-12-21 | Amylin receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20250144A1 true JOP20250144A1 (ar) | 2025-06-16 |
Family
ID=89542238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2025/0144A JOP20250144A1 (ar) | 2022-12-22 | 2025-06-16 | عوامل مساعدة لمستقبل أميلين |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4638480A1 (https=) |
| JP (1) | JP2025542410A (https=) |
| KR (1) | KR20250127104A (https=) |
| CN (1) | CN120435491A (https=) |
| AU (1) | AU2023411346A1 (https=) |
| CL (1) | CL2025001805A1 (https=) |
| CO (1) | CO2025008319A2 (https=) |
| IL (1) | IL321586A (https=) |
| JO (1) | JOP20250144A1 (https=) |
| MX (1) | MX2025007124A (https=) |
| TW (1) | TW202428309A (https=) |
| WO (1) | WO2024133739A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008006A1 (en) | 1992-09-30 | 1994-04-14 | Zymogenetics, Inc. | Human calcitonin receptor |
| ES2401965T3 (es) | 2009-02-19 | 2013-04-25 | Novo Nordisk A/S | Modificación de Factor VIII |
| JP6121992B2 (ja) | 2011-06-10 | 2017-04-26 | ノヴォ ノルディスク アー／エス | ポリペプチド |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
-
2023
- 2023-12-21 CN CN202380088206.1A patent/CN120435491A/zh active Pending
- 2023-12-21 EP EP23838029.9A patent/EP4638480A1/en active Pending
- 2023-12-21 KR KR1020257023613A patent/KR20250127104A/ko active Pending
- 2023-12-21 WO PCT/EP2023/087353 patent/WO2024133739A1/en not_active Ceased
- 2023-12-21 JP JP2025537069A patent/JP2025542410A/ja active Pending
- 2023-12-21 TW TW112150026A patent/TW202428309A/zh unknown
- 2023-12-21 IL IL321586A patent/IL321586A/en unknown
- 2023-12-21 AU AU2023411346A patent/AU2023411346A1/en active Pending
-
2025
- 2025-06-16 JO JOJO/P/2025/0144A patent/JOP20250144A1/ar unknown
- 2025-06-17 CL CL2025001805A patent/CL2025001805A1/es unknown
- 2025-06-18 MX MX2025007124A patent/MX2025007124A/es unknown
- 2025-06-20 CO CONC2025/0008319A patent/CO2025008319A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202428309A (zh) | 2024-07-16 |
| KR20250127104A (ko) | 2025-08-26 |
| CN120435491A (zh) | 2025-08-05 |
| EP4638480A1 (en) | 2025-10-29 |
| CO2025008319A2 (es) | 2025-07-17 |
| CL2025001805A1 (es) | 2025-09-26 |
| MX2025007124A (es) | 2025-07-01 |
| JP2025542410A (ja) | 2025-12-25 |
| IL321586A (en) | 2025-08-01 |
| AU2023411346A1 (en) | 2025-07-24 |
| WO2024133739A1 (en) | 2024-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000872A (es) | Coagonistas de los receptores de peptido-1 similar a glucagon humano (glp-1) y amilina | |
| CY1124052T1 (el) | Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη | |
| AU2014205529B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
| CY1124104T1 (el) | Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη | |
| AR127945A1 (es) | Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| UA122873C2 (uk) | Контрацептивний засіб на основі дроспіренону для пацієнтки, що страждає від надлишкової маси тіла | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| MA38694A2 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| JOP20250310A1 (ar) | صيغ صيدلية لمساعد مستقبل أميلين ومساعد مستقبل 1-glp مشتملة على سيكلودكسترين | |
| AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
| JOP20250048A1 (ar) | تركيبات للإعطاء عن طريق الفم | |
| EA201992826A1 (ru) | 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ | |
| JOP20250144A1 (ar) | عوامل مساعدة لمستقبل أميلين | |
| WO2021144478A8 (en) | Combination treatment for fumarate-related diseases | |
| Curran et al. | Rezolsta®(Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat. | |
| Naccarato et al. | A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy | |
| MX2024001230A (es) | Anticoncepcion oral con progestageno solo. | |
| CY1120847T1 (el) | Σχημα αγωγης ενωσης τιακουμικινης | |
| Mermi et al. | Peripheral edema related to paroxetine discontinuation: a case report | |
| PL425832A1 (pl) | Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera | |
| EA201992690A1 (ru) | Применение вибегрона для лечения гиперактивного мочевого пузыря | |
| EA202191531A1 (ru) | Терапевтически активные стероидные производные |